138 related articles for article (PubMed ID: 23645578)
1. The relationship between depressive symptoms and erythropoietin resistance in stable hemodialysis patients with adequate iron stores.
Afsar B
Int J Artif Organs; 2013 May; 36(5):314-9. PubMed ID: 23645578
[TBL] [Abstract][Full Text] [Related]
2. The relationship between red cell distribution width with erythropoietin resistance in iron replete hemodialysis patients.
Afsar B; Saglam M; Yuceturk C; Agca E
Eur J Intern Med; 2013 Apr; 24(3):e25-9. PubMed ID: 23246125
[TBL] [Abstract][Full Text] [Related]
3. IL-6 is an independent risk factor for resistance to erythropoiesis-stimulating agents in hemodialysis patients without iron deficiency.
Won HS; Kim HG; Yun YS; Jeon EK; Ko YH; Kim YS; Kim YO; Yoon SA
Hemodial Int; 2012 Jan; 16(1):31-7. PubMed ID: 22284696
[TBL] [Abstract][Full Text] [Related]
4. Relationship between insulin resistance and erythropoietin responsiveness in hemodialysis patients.
Abe M; Okada K; Soma M; Matsumoto K
Clin Nephrol; 2011 Jan; 75(1):49-58. PubMed ID: 21176750
[TBL] [Abstract][Full Text] [Related]
5. Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response.
Gaweda AE; Goldsmith LJ; Brier ME; Aronoff GR
Clin J Am Soc Nephrol; 2010 Apr; 5(4):576-81. PubMed ID: 20110344
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D supplementation and recombinant human erythropoietin utilization in vitamin D-deficient hemodialysis patients.
Kumar VA; Kujubu DA; Sim JJ; Rasgon SA; Yang PS
J Nephrol; 2011; 24(1):98-105. PubMed ID: 20563998
[TBL] [Abstract][Full Text] [Related]
7. Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.
Ogawa T; Shimizu H; Kyono A; Sato M; Yamashita T; Otsuka K; Nitta K
Int Urol Nephrol; 2014 Jan; 46(1):151-9. PubMed ID: 23807369
[TBL] [Abstract][Full Text] [Related]
8. Inflammation and resistance to treatment with recombinant human erythropoietin.
Del Vecchio L; Pozzoni P; Andrulli S; Locatelli F
J Ren Nutr; 2005 Jan; 15(1):137-41. PubMed ID: 15648023
[TBL] [Abstract][Full Text] [Related]
9. Relationship between erythropoietin responsiveness, insulin resistance, and malnutrition-inflammation-atherosclerosis (MIA) syndrome in hemodialysis patients with diabetes.
Abe M; Okada K; Maruyama T; Maruyama N; Matsumoto K; Soma M
Int J Artif Organs; 2011 Jan; 34(1):16-25. PubMed ID: 21298620
[TBL] [Abstract][Full Text] [Related]
10. The impact of hyporesponsiveness to erythropoietin-stimulating agents on time-dependent mortality risk among CKD stage 5D patients: a single-center cohort study.
Ishigami J; Onishi T; Shikuma S; Akita W; Mori Y; Asai T; Kuwahara M; Sasaki S; Tsukamoto Y
Clin Exp Nephrol; 2013 Feb; 17(1):106-14. PubMed ID: 22752396
[TBL] [Abstract][Full Text] [Related]
11. Carbamylation of serum albumin and erythropoietin resistance in end stage kidney disease.
Kalim S; Tamez H; Wenger J; Ankers E; Trottier CA; Deferio JJ; Berg AH; Karumanchi SA; Thadhani RI
Clin J Am Soc Nephrol; 2013 Nov; 8(11):1927-34. PubMed ID: 23970130
[TBL] [Abstract][Full Text] [Related]
12. Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy.
Foley RN; Curtis BM; Parfrey PS
Clin J Am Soc Nephrol; 2008 Nov; 3(6):1669-75. PubMed ID: 18922988
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human erythropoietin independence in chronic hemodialysis patients: clinical features, iron homeostasis and erythropoiesis.
Kuo CC; Lee CT; Chuang CH; Su Y; Chen JB
Clin Nephrol; 2005 Feb; 63(2):92-7. PubMed ID: 15730050
[TBL] [Abstract][Full Text] [Related]
14. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
15. Dialysis patients with the metabolic syndrome need less recombinant human erythropoietin for similar hemoglobin levels.
Uyar ME; Tutal E; Bal Z; Sezer S
Transplant Proc; 2013; 45(10):3481-4. PubMed ID: 24314937
[TBL] [Abstract][Full Text] [Related]
16. Anemia management with darbepoetin-alfa in outpatient hemodialysis patients switched from epoetin-alfa: a community hospital experience.
Agrawal V; Mukherjee S; Kosuri R; Dumler F
Am J Ther; 2010; 17(5):469-75. PubMed ID: 19770634
[TBL] [Abstract][Full Text] [Related]
17. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and related factors of the absence of anemia among Chinese chronic hemodialysis patients: a multicenter cross-sectional study.
Wan Q; He Y; Zhang W; Wu Q; Xiong Z
Int Urol Nephrol; 2014 Aug; 46(8):1651-4. PubMed ID: 24114285
[TBL] [Abstract][Full Text] [Related]
19. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
[TBL] [Abstract][Full Text] [Related]
20. Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL.
Bradbury BD; Danese MD; Gleeson M; Critchlow CW
Clin J Am Soc Nephrol; 2009 Mar; 4(3):630-7. PubMed ID: 19261826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
